alexa A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers.
Immunology

Immunology

Journal of Clinical & Cellular Immunology

Author(s): Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K,

Abstract Share this page

Abstract PURPOSE: The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer. METHODS: In 2005, 387 Japanese institutions submitted information regarding the prognosis and clinicopathologic profiles of patients who underwent pulmonary resections for primary lung neoplasms in 1999 to the Japanese Joint Committee of Lung Cancer Registry. The data of 13,010 patients with only lung carcinoma histology (97.6\%) were analyzed in terms of prognosis and clinicopathologic characteristics. RESULTS: The 5-year survival rate of the entire group was 61.4\%. For the small cell histology (n = 390), the 5-year survival rates according to clinical (c) and pathologic (p) stages were as follows: 58.8\% (n = 161) and 58.3\% (n = 127) for IA, 58.0\% (n = 77) and 60.2\% (n = 79) for IB, 47.1\% (n = 17) and 40.6\% (n = 29) for IIA, 25.3\% (n = 38) and 41.1\% (n = 29) for IIB, 29.0\% (n = 61) and 28.3\% (n = 60) for IIIA, 36.3\% (n = 19) and 34.6\% (n = 40) for IIIB, and 27.8\% (n = 12) and 30.8\% for IV (n = 13). For the non-small cell histology (n = 12,620), the 5-year survival rates according to c-stage and p-stage were as follows: 77.3\% (n = 5642) and 83.9\% (n = 4772) for IA, 59.8\% (n = 3081) and 66.3\% (n = 2629) for IB, 54.1\% (n = 205) and 61.0\% (n = 361) for IIA, 43.9\% (n = 1227) and 47.4\% (n = 1330) for IIB, 38.3\% (n = 1628) and 32.8\% (n = 1862) for IIIA, 32.6\% (n = 526) and 29.6\% (n = 1108) for IIIB, and 26.5\% (n = 198) and 23.1\% (n = 375) for IV. Adenocarcinoma, female gender, and age less than 50 years were significant favorable prognostic factors. CONCLUSION: This large registry study provides benchmark prognostic statistics for lung cancer. The prognostic difference between stages IB and IIA was small despite different stages. Otherwise, the present tumor, node, metastasis staging system well characterizes the stage-specific prognoses. This article was published in J Thorac Oncol and referenced in Journal of Clinical & Cellular Immunology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords